The British drugmaker hopes to complete tests by the end of 2021 to confirm whether the antibody-based drug is effective against all the different mutations seen with the new mutant.
Thursday’s announcement is one of the first indications that at least some of the existing anti-Covid-19 treatments will retain their efficacy against the emerging mutated strain.
The drug company, “Regeneron”, warned, on Tuesday, that the combination of antibodies appears to be losing its effectiveness against “Omicron”.
Antibody-based therapies remain one of the few drugs that can mitigate the worst effects of Covid-19, and they are the only option available for people with mild to moderate cases who have not yet been hospitalized.
These drugs are lab-made versions of antibodies that counteract the virus and that the immune system uses to defend the body against infection.
The US government has purchased millions of doses of antibody treatments made by GlaxoSmithKline, Regeneron and Eli Lilly and distributed them to states across the country.
It is noteworthy that the drug “GlaxoSmithKline”, which depends on antibodies, was also approved in Britain, Canada, Australia and Japan.
.